AI Drug Developer Iambic Therapeutics Eyes Nasdaq Debut With $100M Target

Key Highlights

• AI-focused drug developer Iambic Therapeutics, supported by Nvidia and Qatar Investment Authority, has submitted documents for a Nasdaq listing using ticker symbol “IAM”
• The biotechnology firm seeks to secure as much as $100 million to push forward its oncology drug portfolio
• The company’s primary candidate IAM1363 represents an oral HER2 inhibitor currently undergoing Phase 1/1b testing for various solid tumors
• Since launching in 2019, Iambic has secured approximately $461.8 million in funding and established collaborations with major pharma players including AbbVie, Takeda, and others
• The biotech sector is demonstrating exceptional IPO performance in 2026, claiming all five top positions among major debuts this year

Iambic Therapeutics, a biotechnology venture utilizing artificial intelligence for drug discovery and supported by Nvidia alongside Qatar’s sovereign investment vehicle, submitted its application for a United States public offering this Monday. The California-based pharmaceutical company intends to trade on the Nasdaq exchange using the ticker symbol “IAM.”

According to Renaissance Capital’s analysis, the proposed offering targets up to $100 million in capital. The filing documents did not specify a pricing range for shares.

Iambic’s Business Model and Technology

Established in 2019 operating initially as Entos, Iambic leverages artificial intelligence technology combined with automated chemical and biological platforms to identify small-molecule therapeutic compounds. The company concentrates its research efforts on addressing solid tumor cancers.

The firm’s flagship therapeutic candidate, designated IAM1363, functions as an experimental oral HER2 inhibitor. This compound is presently undergoing Phase 1/1b early-stage clinical evaluation for multiple solid tumor types, including breast cancer cases.

Additional pipeline programs designated IAM217 and IAM-C1 are currently in preclinical research stages. Management intends to allocate IPO capital toward progressing all three therapeutic candidates through successive clinical trial phases.

The company has accumulated approximately $461.8 million in investment funding since inception. The investor roster features Nvidia, Qatar Investment Authority, Catalio, Nexus Ventures, and Coatue Management.

Coinciding with its IPO submission, Iambic revealed a comprehensive multi-year partnership with AbbVie focused on accelerating AI-powered discovery of small molecule treatments. Additional strategic alliances exist with Takeda, Lundbeck, Revolution Medicines, Jazz Pharmaceuticals, and Bayer.

The offering’s underwriting syndicate includes J.P. Morgan, Jefferies, BofA Securities, and Citigroup.

Biotechnology Sector Leads IPO Performance

Iambic joins several other companies pursuing autumn listings. Pharmaceutical developers Retension Pharmaceuticals and TRex Bio submitted their US IPO applications this past Friday. Meanwhile, ADARx Pharmaceuticals initiated its investor roadshow concurrent with Iambic’s filing.

Biotechnology offerings have demonstrated resilience throughout 2026 despite headwinds affecting the general IPO landscape. Concerns surrounding the Iran conflict, climbing treasury yields, and monetary policy tightening have created challenges across numerous industries.

Renaissance Capital’s senior strategist Matt Kennedy noted that every one of this year’s five strongest-performing IPOs exceeding $50 million in size comes from the biotechnology field. He identified therapeutic progress and corporate acquisition momentum as primary catalysts.

Market observers suggest biotech IPOs have maintained significant isolation from widespread market turbulence. An uptick in acquisitions by major pharmaceutical corporations has bolstered sector sentiment and investor confidence.

Iambic’s submission contributes to what appears to be a robust autumn season for biotechnology public listings.